Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. Issue 17 (November 2015)

• Record Type: Journal Article
• Authors: de Azambuja, Evandro; Ameye, Lieveke; Diaz, Marie; Vandenbossche, Sandrine; Aftimos, Philippe; Hernández, Sara Bejarano; Shih-Li, Chao; Delhaye, François; Focan, Christian; Cornez, Nathalie; Vindevoghel, Anita; Beauduin, Marc; Lemort, Marc; Paesmans, Marianne; Suter, Thomas; Piccart-Gebhart, Martine
• Is Part Of: European journal of cancer. Volume 51:Issue 17(2015:Nov.)
• Page Start: 2517
• Page End: 2524
• Publication Date: 2015-11
• Subjects: Adjuvant therapy -- Node-positive breast cancer -- Late cardiac toxicity; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2015.08.011
• Languages: English
• ISSNs: 0959-8049

Abstract

Highlights: 82 patients (30%) out of 269 eligible patients accepted to participate. This is one of the longest follow-up (median 18 years) in breast cancer patients. Epirubicin-treated patients had significantly higher heart rate, more abnormal US and lower LVEF by MRI. A trend towards higher BNP was also observed in the anthracycline-treated group. No differences were observed in LVEF assessed by echocardiogram or troponin T levels. Abstract: Background: Epirubicin-based chemotherapy improves the outcome of early breast cancer (BC) patients. However, cardiotoxicity remains an important side effect. Methods: We re-consented node-positive BC patients enrolled in a phase III trial between 1988 and 1996 which compared six cycles of oral cyclophosphamide, methotrexate, fluorouracil (CMF) versus two epirubicin–cyclophosphamide regimens differing by the anthracycline cumulative dose [standard-dose epirubicin and cyclophosphamide (SDE) (8 × 60 mg/m 2 ) and higher-dose epirubicin and cyclophosphamide (HDE) (8 × 100 mg/m 2 )]. Eligible patients were those who were alive and free of disease and had no contra-indications to the proposed tests (cardiac evaluation). Cardiotoxicity was defined as asymptomatic systolic dysfunction (left ventricular ejection fraction (LVEF) < 50%, New York Heart Association (NYHA) Class I) or symptomatic heart failure (NYHA Class II–IV). Differences in cardiotoxicity between CMF and SDE/HDE were assessed using chi-square and Fisher Exact tests for binary variables and t -test and Wilcoxon test for continuous variables. Results: Among the 777 patients, 20 cases of CHF were reported (CMF = 1, SDE = 5, HDE = 14; p < 0.001). Between September 2010 and June 2013, 82 patients (30%) out of 269 eligible patients accepted to participate in this substudy. Median follow-up was 18 years (range 15–24). Epirubicin-treated patients had significantly higher heart rate, more abnormal echocardiograms and LVEF by magnetic resonance imaging (MRI) compared to CMF-treated ones. A trend towards higher BNP was also observed in the SDE/HDE group ( P = 0.08). No differences were observed in LVEF assessed by echocardiogram or troponin T levels. Conclusions: Participation rate in this substudy was lower than expected highlighting the complexity of re-calling patients several years after the initial BC diagnosis. After 18 years, epirubicin-treated patients had a lower LVEF by MRI, more abnormal echocardiograms, higher heart rates compared to patients treated with CMF. However, no major delayed cardiotoxicity was observed.